UA103015C2 - Новые производные инсулина с чрезвычайно замедленным профилем время/действие - Google Patents
Новые производные инсулина с чрезвычайно замедленным профилем время/действиеInfo
- Publication number
- UA103015C2 UA103015C2 UAA201009821A UAA201009821A UA103015C2 UA 103015 C2 UA103015 C2 UA 103015C2 UA A201009821 A UAA201009821 A UA A201009821A UA A201009821 A UAA201009821 A UA A201009821A UA 103015 C2 UA103015 C2 UA 103015C2
- Authority
- UA
- Ukraine
- Prior art keywords
- amino acid
- action profile
- radical
- novel insulin
- delayed time
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретение относится к новым аналогам инсулина с базальным профилем время/действие, которые отличаются тем, что а) конец В-цепи (В32) содержит амидированный лизин или амидированный аргинин, b) N-терминальный аминокислотный остаток инсулина А-цепи является лизиновым или аргининовым остатком, с) позиция аминокислоты А8 занята гистидиновым остатком, d) позиция аминокислоты А21 занята глициновым остатком, и e) одно или несколько замещений и/или присоединений отрицательно заряженных аминокислотных остатков проводят в позициях А5, А15, А18, В-1, В0, В1, В2, В3 и В4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE200810003568 DE102008003568A1 (de) | 2008-01-09 | 2008-01-09 | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
PCT/EP2009/000017 WO2009087081A2 (de) | 2008-01-09 | 2009-01-06 | Neue insulinderivate mit extrem verzögertem zeit-/wirkungsprofil |
Publications (1)
Publication Number | Publication Date |
---|---|
UA103015C2 true UA103015C2 (ru) | 2013-09-10 |
Family
ID=40758369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201009821A UA103015C2 (ru) | 2008-01-09 | 2009-01-06 | Новые производные инсулина с чрезвычайно замедленным профилем время/действие |
Country Status (3)
Country | Link |
---|---|
CR (1) | CR11511A (ru) |
DE (1) | DE102008003568A1 (ru) |
UA (1) | UA103015C2 (ru) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009038210A1 (de) | 2009-08-20 | 2011-03-03 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
DE102008053048A1 (de) | 2008-10-24 | 2010-04-29 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
DE102008051834A1 (de) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
HUE037449T2 (hu) | 2008-10-17 | 2018-08-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
AU2008365555B2 (en) | 2008-12-15 | 2016-01-14 | Zealand Pharma A/S | Glucagon analogues |
MX2011006314A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
EA020596B1 (ru) | 2008-12-15 | 2014-12-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
BRPI0823379A2 (pt) | 2008-12-15 | 2015-07-14 | Zealand Pharma As | Análogos de glucagon |
JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
KR101759499B1 (ko) | 2009-07-31 | 2017-07-19 | 사노피-아벤티스 도이칠란트 게엠베하 | 지속형 인슐린 조성물 |
EP2459228B1 (en) | 2009-07-31 | 2020-03-04 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an insulin linker conjugate |
PE20121316A1 (es) | 2009-11-13 | 2012-10-05 | Sanofi Aventis Deutschland | Composicion farmaceutica que comprende un agonista de glp-1 y metionina |
RU2537239C2 (ru) | 2009-11-13 | 2014-12-27 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин |
AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
AU2011269430A1 (en) | 2010-06-24 | 2013-01-10 | Zealand Pharma A/S | Glucagon analogues |
PT2611458T (pt) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2 |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
EA201390796A1 (ru) | 2011-01-20 | 2014-07-30 | Зилэнд Фарма А/С | Применение ацилированного аналога глюкагона |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
PT2750699E (pt) | 2011-08-29 | 2015-11-03 | Sanofi Aventis Deutschland | Acelerómetro pendular |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
CA2872314C (en) | 2012-05-03 | 2021-08-31 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
PL2854841T3 (pl) | 2012-06-04 | 2017-08-31 | Diamedica Inc. | Izoformy glikozylacji ludzkiej kalikreiny tkankowej 1 |
MY170671A (en) | 2012-07-23 | 2019-08-26 | Zealand Pharma As | Glucagon analogues |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
HUE039616T2 (hu) | 2013-10-17 | 2019-01-28 | Zealand Pharma As | Acilezett glükagon analógok |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
BR112016009995B1 (pt) | 2013-11-06 | 2023-04-18 | Zealand Pharma A/S | Compostos agonistas triplos glucagon-glp-1-gip |
AU2014345569B2 (en) | 2013-11-06 | 2020-08-13 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
MA43289B1 (fr) | 2014-01-20 | 2019-12-31 | Hanmi Pharm Ind Co Ltd | Insuline à action prolongée et utilisation associée |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
AR100695A1 (es) | 2014-05-30 | 2016-10-26 | Hanmi Pharm Ind Co Ltd | Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón |
CA2965732A1 (en) | 2014-10-29 | 2016-05-06 | Zealand Pharma A/S | Gip agonist compounds and methods |
CA2970200A1 (en) | 2014-12-12 | 2016-06-16 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
KR20170137198A (ko) | 2015-04-16 | 2017-12-12 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
WO2018056764A1 (ko) | 2016-09-23 | 2018-03-29 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도 |
JP2020510023A (ja) | 2017-03-09 | 2020-04-02 | ダイアメディカ, インコーポレイテッド | 組織カリクレイン1の剤形 |
TWI798209B (zh) | 2017-03-23 | 2023-04-11 | 南韓商韓美藥品股份有限公司 | 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
IL95495A (en) | 1989-08-29 | 1996-10-16 | Hoechst Ag | Fusion proteins their preparation and use |
DE4405388A1 (de) | 1994-02-19 | 1995-08-24 | Hoechst Ag | Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen |
UA72181C2 (ru) | 1996-08-30 | 2005-02-15 | Ново Нордіск А/С | Translated By PlajПРОИЗВОДНЫЕ ГЛЮКАГОНООБРАЗНОГО ПЕПТИДА-1 |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
DE19947456A1 (de) | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga |
DE10108212A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände |
WO2004005342A1 (en) | 2002-07-04 | 2004-01-15 | Zealand Pharma A/S | Glp-1 and methods for treating diabetes |
DE102004058306A1 (de) | 2004-12-01 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden |
AU2006291780B2 (en) | 2005-09-14 | 2011-12-08 | F. Hoffmann-La Roche Ag | Cleavage of precursors of insulins by a variant of trypsin |
-
2008
- 2008-01-09 DE DE200810003568 patent/DE102008003568A1/de not_active Withdrawn
-
2009
- 2009-01-06 UA UAA201009821A patent/UA103015C2/ru unknown
-
2010
- 2010-06-17 CR CR11511A patent/CR11511A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CR11511A (es) | 2010-09-13 |
DE102008003568A1 (de) | 2009-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2010000298A1 (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
UA103015C2 (ru) | Новые производные инсулина с чрезвычайно замедленным профилем время/действие | |
WO2009087082A3 (de) | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil | |
SG191069A1 (en) | Cyclosporine analogue molecules modified at amino acid 1 and 3 | |
PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
NZ743910A (en) | Purification of iduronate-2-sulfatase | |
MX337038B (es) | Co-antagonistas de receptor de glucagon/glp-1. | |
MX2020004912A (es) | Compuestos derivados de prostaciclinas, y el uso de los mismo para el tratamiento de la hipertension pulmonar. | |
MX364911B (es) | Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial. | |
WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
MX2010004571A (es) | Composiciones y metodos que comprenden peptidos y proteasas de aminoacidos basicos. | |
CA2651990C (en) | Improved antimicrobial peptides | |
WO2010085700A3 (en) | Treatment for obesity | |
NZ595242A (en) | Improved anti-serum albumin binding variants | |
MX353301B (es) | Composiciones tripeptidicas y metodos para tratamiento de diabetes. | |
BR112014013367A2 (pt) | polipeptídeo | |
IN2014DN09367A (ru) | ||
WO2013151467A3 (ru) | Способ получения рекомбинантного пептида и полученный пептид | |
BR112017019241A2 (pt) | análogo peptídico, composição, método para induzir uma resposta imune contra uma infecção, kit, composto e uso de um análogo peptídico | |
WO2011061720A3 (en) | Viral citrullinated peptides and uses thereof | |
MX2010011055A (es) | Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas. | |
NZ706202A (en) | Peptide antagonists of the vasopressin-2 receptor | |
EA201101285A1 (ru) | Антагонистические пептиды к frizzled-1 и frizzled-2 рецепторам | |
MY155338A (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
WO2010114909A8 (en) | Sulfonyl-piperidin-4-yl methylamine amide analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders |